Patient,Age,Sex,Antibody,Acute VGKCC Ab titre (pmol/L),Onset to study inclusion (years),Onset to immunosuppressive treatment (months),Latest seizure to study inclusion (years),Seizure type,Immunotherapy,Acute HPC T2 signal,Acute HPC volume,Acute HPC diffusion,Acute extra-HPC abnormalities,Follow-up HPC volume (z)
1,73.19,M,LGI1,4717,7,3,>4,GTCS; SPS,Oral steroids; PLEX; IVIG,R: normalL: very high,R: normalL: very enlarged,R: facilitatedL: normal,L AMG: high T2 signal,R: −1.84L: −2.68
2,76.04,F,VGKCC,801,6,1,<1,CPS; FBDS,Oral steroids; IVIG,R: normalL: high,R: mildly atrophicL: normal,R: facilitatedL: facilitated,–,R: −1.40L: −2.12
3,68.58,M,VGKCC,1936,6,12,>4,GTCS; CPS,Oral steroids; IVIG,R: normalL: very high,R: normalL: very enlarged,R: facilitatedL: normal,"L AMG, L ERC: high T2 signal",R: 1.75L: −0.03
4,53.21,M,LGI1,336*,7,<1,>6,MCS,Oral steroids; IVIG,R: highL: normal,R: normalL: normal,R: normalL: facilitated,–,R: −4.67L: −3.69
5,68.85,M,LGI1,1500,13,<1,>11,PCS; GTCS,Oral steroids; PLEX; IVIG,R: normal†L: normal†,R: normal†L: normal†,n/a†,–,R: −1.74L: −2.27
6,64.44,M,LGI1,1735,6,8,>5,FBDS,Oral steroids; PLEX; IVIG,R: normalL: normal,R: normalL: normal,,–,R: −0.58L: −0.22
7,66.92,M,LGI1,416,11,5,>10,GTCS; CPS,PLEX; IVIG,R: normalL: high,R: normalL: enlarged,,L/R AMG: high T2 signal,R: 1.79L: 2.20
8,79.57,M,LGI1,4950,3,3,>1,GTCS; CPS,Oral steroids; PLEX; IVIG,R: highL: high,R: normalL: normal,R: normalL: facilitated,–,R: −0.59L: 0.89
9,57.38,M,LGI1,3422,2,3,>1,CPS,Oral steroids; PLEX,R: very highL: high,R: enlargedL: enlarged,R: normalL: normal,–,R: −1.32L: −1.06
10,57.39,M,LGI1,1306,9,38,<1,MCS,Oral steroids,n/a‡,n/a‡,n/a‡,–,R: −3.96L: −5.30
11,46.7,M,LGI1,2249,1,3,<1,CPS,Oral steroids; IVIG,R: very highL: high,R: normalL: normal,,–,R: −1.95L: −2.17
12,55.05,M,LGI1/CASPR2,1228,9,2,>1,GTCS; CPS,Oral steroids; IVIG,R: highL: normal,R: atrophicL: normal,,–,R: −2.58L: −0.28
13,38.08,M,LGI1/CASPR2,378§,2,<1,>2,,Oral steroids; IVIG,R: normalL: normal,R: mildly atrophicL: mildly atrophic,R: normalL: normal,–,R: −3.47L: −2.97
14,82.46,M,LGI1,956,10,2,>9,,Oral steroids; IVIG,R: highL: normal,R: mildly atrophicL: mildly atrophic,R: facilitatedL: facilitated,–,R: −3.23L: −2.06
15,55.18,M,LGI1,4091,3,12,>1,GTCS; CPS,Oral steroids,R: very highL: normal,R: normalL: normal,R: facilitatedL: facilitated,–,R: −4.47L: −2.71
16,56.03,M,LGI1/CASPR2,2878,4,7,>2,GTCS; CPS; MCS,Oral steroids; PLEX,R: very highL: normal,R: very enlargedL: normal,R: facilitatedL: facilitated,–,R: −1.49L: −3.31
17,56.93,M,VGKCC,1032,5,2,<1,CPS,Oral steroids; PLEX; IVIG,R: highL: normal,R: enlargedL: normal,,–,R: −1.49L: −2.27
18,76.59,M,LGI1,1430,2,3,<1,GTCS; CPS; MCS; FBDS,Oral steroids; IVIG,R: highL: high,R: enlargedL: enlarged,R: normalL: normal,L/R AMG: high T2 signal; enlarged,R: −0.03L: 0.27
19,79.0,M,LGI1/CASPR2,1116,<1,3,<1,CPS,Oral steroids; IVIG,R: highL: high,R: mildly atrophicL: normal,R: normalL: normal,–,R: −0.04L: 0.80
20,53.83,F,LGI1,1094,<1,2,<1,CPS,Oral steroids; IVIG,R: highL: high,R: normalL: normal,R: normalL: normal,–,R: −0.49L: −0.72
21,75.07,F,VGKCC,,1,,>1,,Oral steroids; IVIG,R: very highL: very high,R: enlargedL: enlarged,R: facilitatedL: facilitated,–,R: −1.44L: −2.70
22,65.32,M,LGI1,1400,2,2,>1,,Oral steroids,R: highL: high,R: normalL: normal,R: normalL: normal,–,R: −1.30L: −1.05
23,66.25,M,VGKCC,949,5,44,>5,,IVIG,R: normalL: normal,R: normalL: normal,R: normalL: normal,–,R: 0.37L: 0.28
24,60.49,M,VGKCC,,6,n/a†‡§,>3,FBDS,Oral steroids; PLEX; IVIG,R: highL: high,R: atrophicL: atrophic,R: normalL: normal,L/R AMG: high T2 signal; atrophy,R: −4.49L: −3.51
